Montag A & Associates Inc. Acquires 2,090 Shares of Iqvia Holdings Inc (NYSE:IQV)

Montag A & Associates Inc. lifted its holdings in shares of Iqvia Holdings Inc (NYSE:IQV) by 3.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 59,307 shares of the medical research company’s stock after purchasing an additional 2,090 shares during the quarter. Montag A & Associates Inc.’s holdings in Iqvia were worth $8,859,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Oppenheimer & Co. Inc. increased its holdings in shares of Iqvia by 2.0% during the second quarter. Oppenheimer & Co. Inc. now owns 5,322 shares of the medical research company’s stock worth $856,000 after purchasing an additional 102 shares during the period. Parallel Advisors LLC increased its holdings in shares of Iqvia by 27.0% during the second quarter. Parallel Advisors LLC now owns 512 shares of the medical research company’s stock worth $82,000 after purchasing an additional 109 shares during the period. APG Asset Management N.V. increased its holdings in shares of Iqvia by 120.8% during the second quarter. APG Asset Management N.V. now owns 34,000 shares of the medical research company’s stock worth $4,804,000 after purchasing an additional 18,600 shares during the period. National Asset Management Inc. increased its holdings in shares of Iqvia by 6.6% during the second quarter. National Asset Management Inc. now owns 3,787 shares of the medical research company’s stock worth $610,000 after purchasing an additional 234 shares during the period. Finally, Flinton Capital Management LLC increased its holdings in shares of Iqvia by 455.3% during the second quarter. Flinton Capital Management LLC now owns 85,988 shares of the medical research company’s stock worth $13,836,000 after purchasing an additional 70,504 shares during the period. 89.92% of the stock is currently owned by institutional investors.

Several research analysts have recently commented on the stock. ValuEngine cut shares of Iqvia from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Credit Suisse Group lifted their price objective on shares of Iqvia from $165.00 to $170.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. Wells Fargo & Co lifted their price objective on shares of Iqvia from $170.00 to $178.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. JPMorgan Chase & Co. lifted their price objective on shares of Iqvia from $160.00 to $180.00 and gave the company an “overweight” rating in a research note on Thursday, July 25th. Finally, Barclays set a $180.00 price objective on shares of Iqvia and gave the company a “buy” rating in a research note on Monday, July 15th. Four equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. Iqvia presently has a consensus rating of “Buy” and a consensus target price of $166.46.

NYSE:IQV traded down $0.25 during mid-day trading on Friday, reaching $137.59. The stock had a trading volume of 1,450,481 shares, compared to its average volume of 1,291,668. The stock has a 50-day simple moving average of $147.15 and a two-hundred day simple moving average of $148.22. The stock has a market capitalization of $27.14 billion, a PE ratio of 26.87, a P/E/G ratio of 1.55 and a beta of 0.87. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.12 and a quick ratio of 1.14. Iqvia Holdings Inc has a 12 month low of $104.90 and a 12 month high of $164.13.

Iqvia (NYSE:IQV) last announced its quarterly earnings data on Wednesday, October 30th. The medical research company reported $1.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.03. The business had revenue of $2.77 billion for the quarter, compared to analysts’ expectations of $2.76 billion. Iqvia had a net margin of 2.24% and a return on equity of 16.95%. The firm’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same period last year, the firm posted $1.42 earnings per share. Equities analysts expect that Iqvia Holdings Inc will post 5.9 EPS for the current year.

Iqvia Company Profile

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Story: What is the Beige Book?

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.